Search results for "raf inhibitors"

showing 3 items of 3 documents

Emerging Raf inhibitors

2009

The Raf/MAPK kinase/extracellular-signal-regulated kinase pathway is often activated by genetic alterations in upstream signaling molecules. An integral component of this pathway, BRAF, is also activated by mutation, especially in melanoma and thyroid cancers. The Raf/MAPK kinase/extracellular-signal-regulated kinase pathway has profound effects on proliferative, apoptotic and differentiation pathways as well as the sensitivity and resistance to chemotherapeutic drugs.This review discusses targeting of Raf which could control abnormal proliferation in cancer and other proliferative diseases. The important roles that genetics plays in the response of patients to Raf inhibitors is also evalua…

MAPK/ERK pathwayProto-Oncogene Proteins B-rafCell signalingMAP Kinase Signaling SystemSignal transductionrafmedicine.disease_causemekerkmedicineHumanscancerPharmacology (medical)raf inhibitorsExtracellular Signal-Regulated MAP KinasesMelanomaProtein Kinase InhibitorsPharmacologyapoptosis cancer ERK proliferative disorderssignal transductionMitogen-Activated Protein Kinase KinasesApoptosis; Cancer; ERK; Kinases; MEK; Proliferative disorders; Protein phosphorylation; Raf; Raf inhibitors; Signal transductionMutationproliferative disordersapoptosis; cancer; erk; kinases; mek; proliferative disorders; protein phosphorylation; raf; raf inhibitors; signal transduction read more: http://informahealthcare.com/doi/abs/10.1517/14728210903232633business.industryKinaseMelanomaapoptosisCancermedicine.diseaseXenograft Model Antitumor Assaysprotein phosphorylationCell Transformation Neoplastickinasessignal transduction read more: http://informahealthcare.com/doi/abs/10.1517/14728210903232633ApoptosisDrug Resistance NeoplasmCancer researchSignal transductionMitogen-Activated Protein Kinasesbusiness
researchProduct

BRAF mutations in non-small cell lung cancer : has finally Janus opened the door?

2016

Abstract: B-Raf mutations occur in about 1-2% of non-small cell lung cancers (NSCLC). These mutations generate a permanent activation of the mitogen activated protein kinase (MAPK) pathway, which promotes tumor growth and proliferation. In the present review, we discuss B-Raf mutation epidemiology, diagnostic methods to detect B-Raf mutations, the role of B-Raf as a driver mutation and a potential therapeutic target in NSCLC. The results of clinical trials involving B-Raf or MAPK pathway inhibitors for the treatment of NSCLC are also discussed. Clinical trials evaluating B-Raf inhibitors in BRAF mutated NSCLC patients have shown promising results, and larger prospective studies are warrante…

MAPK/ERK pathwayProto-Oncogene Proteins B-rafmedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentCellProtein Kinase Inhibitormedicine.disease_causeBioinformaticsNSCLCTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungmedicineHumans030212 general & internal medicineB-Raf inhibitorLung cancerProtein Kinase InhibitorsB-Raf inhibitorsMutationHematologybiologybusiness.industryB-RafB-Raf; B-Raf inhibitors; Drug; Mutation; NSCLC; Oncology; Hematology; Geriatrics and GerontologyHematologymedicine.diseaseLung NeoplasmClinical trialmedicine.anatomical_structureOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisMitogen-activated protein kinaseMutationbiology.proteinCancer researchHuman medicineDrugGeriatrics and GerontologybusinessHumanCritical reviews in oncology, hematology
researchProduct

What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment

2015

The RAS-related signalling cascade has a fundamental role in cell. It activates differentiation and survival. It is particularly important one of its molecules, B-RAF. B-RAF has been a central point for research, especially in melanoma. Indeed, it lacked effective therapeutic weapons since the early years of its study. Molecules targeting B-RAF have been developed. Nowadays, two classes of molecules are approved by FDA. Multi-target molecules, such as Sorafenib and Regorafenib, and selective molecules, such as Vemurafenib and Dabrafenib. Many other molecules are still under investigation. Most of them are studied in phase 1 trials. Clinical studies correlate B-RAF inhibitors and QT prolonga…

SorafenibProto-Oncogene Proteins B-rafB-RAF inhibitorscardio-oncologySkin NeoplasmscardiotoxicityAntineoplastic AgentsReviewB-RAF inhibitorPharmacologyQT intervalSudden cardiac deathchemistry.chemical_compoundRegorafenibmedicineAnimalsHumansMolecular Targeted TherapydabrafenibVemurafenibMelanomaProtein Kinase InhibitorsCardiotoxicityClinical Trials as Topicbusiness.industryMelanomaB-RAFDabrafenibArrhythmias CardiacHeartmedicine.diseaseOncologychemistryCancer researchbusinessmedicine.drugSignal TransductionOncotarget
researchProduct